XASE · Healthcare · Biotechnology
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.33 | -0.02 | +93.94% | $0 | ✅ Beat | +1.42% | -27.85% | — |
| 2026-05-14 | Q1 2026 | -0.44 | -0.29 | +34.09% | $0 | ✅ Beat | +1.07% | +2.52% | -10.72% |
| 2026-03-30 |
| Q4 2025 |
| -0.26 |
| -3.72 |
| -1330.77% |
| $0 |
| ❌ Miss |
| +2.07% |
| -8.03% |
| -3.52% |
| 2025-11-14 | Q3 2025 | -0.43 | -0.39 | +9.30% | $0 | ✅ Beat | — | — | — |
| 2025-08-12 | Q2 2025 | -0.35 | -0.60 | -71.43% | $0 | ❌ Miss | +0.10% | +6.07% | +12.30% |
| 2025-03-24 | Q4 2024 | — | 3.75 | — | $0 | — | -7.28% | -19.94% | -39.22% |
| 2024-11-13 | Q3 2024 | -11.52 | -11.52 | +0.00% | $0 | ➖ Inline | -11.35% | -18.33% | -2.33% |
| 2024-08-12 | Q2 2024 | -13.68 | -11.52 | +15.79% | $0 | ✅ Beat | -0.98% | +0.02% | -21.75% |
Showing last 8 quarters.